Given the high incidence of and emerging evidence on newer treatment regimens for HR + HER2 − mBC, an expert panel of nine key opinion leaders from Argentina, Brazil, Colombia, Mexico, Moscow, Singapore, South Korea, Taiwan, and UAE convened in October 2018 in Munich, Germany to: (1) review the current treatment armamentarium; (2) discuss and formulate answers to key clinical questions on optimizing treatment; and (3) examine the feasibility of developing a regional breast cancer registry. The gene discussed is ERBB2; the disease is breast carcinoma.